Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

License and Development Agreement

More Like This

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia

PR Newswire associated0

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

bit.bio's cell therapy pipeline November 2023 (Graphic: Business Wire)

bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy